Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRO: Switching to Abilify Maintena in Schizophrenia
NCT03376763Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole in schizophrenia, sponsored by Otsuka Holdings. Started Nov 2017; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03376763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376763.